A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage (REST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01475474
Recruitment Status : Completed
First Posted : November 21, 2011
Results First Posted : November 28, 2013
Last Update Posted : November 28, 2013
Information provided by (Responsible Party):
Renew Medical

Brief Summary:
The purpose of this study is to determine whether the use of the Renew Insert is effective, tolerable and safe in the treatment of accidental bowel leakage due to bowel incontinence.

Condition or disease Intervention/treatment Phase
Bowel Incontinence Device: Renew Insert Not Applicable

Detailed Description:
Prospective, open label, single-arm, non-randomized, multi-center study designed to evaluate the efficacy, safety and tolerability of the Renew Insert in moderate-to-severe bowel incontinence patients: Minimum Wexner score of 12 AND at least weekly (score 3 or higher) leakage of solid and or liquid type stool.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Prospective, Non-Randomized Study of the Renew Insert Efficacy, Safety and Tolerability For the Management of Accidental Bowel Leakage Due to Bowel Incontinence
Study Start Date : December 2009
Actual Primary Completion Date : November 2011
Actual Study Completion Date : December 2011

Intervention Details:
  • Device: Renew Insert
    The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.

Primary Outcome Measures :
  1. Co-primary Effectiveness Endpoint: A Relative Percentage Change in Episodes of Accidental Bowel Leakage (ABL) Determined by Comparing Treatment Results to Pre-treatment Results From the Baseline Period as Measured by Daily Diary Recordings. [ Time Frame: Reduction in accidental bowel leakage from Baseline (Weeks 1-4) through Treatment period (Weeks 5-16). ]
    This co-primary effectiveness endpoint was calculated as a relative percentage of the baseline Accidental Bowel Leakage (ABL) using the following equation: % reduction in ABL = 100*(baseline period ABL - treatment period ABL) / (baseline period ABL)

  2. Co-primary Effectiveness Endpoint: A Relative Percentage Change in Wexner Score (or Bowel Incontinence) Severity by Comparing Post-treatment Wexner Scores to Pre-treatment (End of Baseline Period) Wexner Scores. [ Time Frame: Wexner score was calculated at the end of the Baseline period (Weeks 1-4) to the end of the 12-Week Treatment Period (week 16). ]

    The Wexner fecal incontinence scale takes into account five parameters that are scored on a scale from zero (absent) to four (daily) frequency of incontinence to gas, liquid, solid, use of pad, and quality of life. Full continence is a Wexner total of zero (0), whereas full incontinence is a Wexner total of 20.

    This co-primary effectiveness endpoint is the mean % reduction in Wexner score from the baseline period to the end of the treatment period, which was calculated according to the following equation: % reduction in Wexner = 100% (baseline period Wexner - end treatment period Wexner) / (baseline period Wexner).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed Informed Consent
  • Minimum Wexner Bowel incontinence score of 12 AND at least weekly (score of 3 or higher) leakage of solid and/or liquid type stool, with no greater than 50% of subjects with daily (score 4) of uncontrolled gas.
  • Patients colon surveillance must be in compliance with American Cancer Society colon screening guidelines. If patient is out of compliance, they may be scheduled for Colonoscopy.
  • Patient comprehends study meaning & is capable of carrying out study duties
  • Fluent in English

Exclusion Criteria:

  • American Society of Anesthesiologist (ASA) score of 4 or higher
  • Spinal cord injury or other major neurological diagnosis
  • Known immune deficiency state
  • Significant cardiac arrhythmia
  • Pregnant or Breastfeeding
  • Inflammatory bowel disease
  • Requirement of medication delivered by suppository
  • Active perianal abscess or fistula
  • Present rectal prolapse
  • Third degree hemorrhoids
  • Anal stricture
  • History or rectal spasm
  • Rectal surgery in past 6 months
  • Unresolved Anismus
  • Fecal impaction with overflow diarrhea
  • Ileo-anal pouch
  • Rectocele requiring surgery
  • Allergy to silicone or one of its components
  • Significant medical condition which interferes with study participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01475474

United States, California
Dr. Segall
Los Gatos, California, United States, 95032
UCSD Medical Center
San Diego, California, United States, 92103-8897
United States, Florida
Cleveland Clinic Florida
Weston, Florida, United States, 33331
Sponsors and Collaborators
Renew Medical
Principal Investigator: Steven D Wexner, MD Cleveland Clinic Florida
Principal Investigator: Emily Lukacz, MD University of California, San Diego, CA
Principal Investigator: Mark Segall, MD The medical office of Mark Segall MD
Principal Investigator: Eric G Weiss, MD Cleveland Clinic Florida

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Renew Medical Identifier: NCT01475474     History of Changes
Other Study ID Numbers: Renew Medical - 210CLD
First Posted: November 21, 2011    Key Record Dates
Results First Posted: November 28, 2013
Last Update Posted: November 28, 2013
Last Verified: September 2013

Keywords provided by Renew Medical:

Additional relevant MeSH terms:
Fecal Incontinence
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases